Dey Lab

Excited to share our latest work from the lab, now published in Neuro-Oncology!

In this study, we explored a novel radiopharmaceutical therapy approach for leptomeningeal metastasis — one of the most devastating complications of solid tumors involving the central nervous system. Current treatments offer limited benefit and can cause significant toxicity.

Using tumor-targeting alkylphosphocholine NM600 labeled with Actinium-225, we demonstrated:
🧠 Improved tumor targeting within the leptomeningeal space
🎯 Greater anti-tumor efficacy compared with conventional external beam radiation
🛡️ Reduced off-target CNS toxicity
⏳ Significant survival benefit in preclinical models of breast and lung cancer leptomeningeal metastasis

These findings support the potential of targeted alpha-particle radiopharmaceutical therapy as a new therapeutic strategy for patients with CNS metastatic disease.

Proud of this incredible multidisciplinary team and grateful to all our collaborators who made this work possible. Special congratulations to the trainees and co-authors whose dedication drove this project forward.

🧠 New Insights into Cavernous Sinus Meningiomas

Don’t miss the next installment of Latest Highlights in Neurosurgical Oncology, featuring a deep dive into one of the most complex areas of skull base surgery.

Join world renowned Dr. Jacques Morcos for an expert session on the management and surgical nuances of Cavernous Sinus Meningiomas.

🗓️ Event Details
• Date: Wednesday, April 8th
• Time: 3:30 PM CST
• Host: Dr. Yoshua Esquenazi (UT Health Houston)

🎙️ Featured Panelists
• Dr. Costas Hadjipanayas
• Dr. Mahua Dey
• Dr. Spyros Karadimas
• Dr. Hussam Abou-Al-Shaar

🔗 How to Join
Join the conversation and stay at the forefront of neuro-oncology. Register or join the session directly via the link below or by scanning the QR code in the image:
👉 rebrand.ly/q5mbl6t

Welcome to the Greatest Field in Medicine 🧠⚡️
Huge congratulations to the newest cohort of Neurosurgery residents! 🥂 You’ve officially matched into the most demanding, exhilarating, and rewarding specialty in existence.
The road ahead is long, and the training is legendary for its intensity—but the privilege of holding a human life (and their entire world) in your hands is a reward that words can’t quite capture.
To the Match Class of 2026:
• Prepare for the steepest learning curve of your life. 📈
• Embrace the late nights and the complex cases.
• Welcome to the family. We can't wait to see what you achieve.
Drop a 🧠 or a 🔪 in the comments if you’re joining the ranks today!

🌸 Fertility. Cancer. The Questions We Don’t Ask Enough. 🌸

In our previous research on glioma and pregnancy, our team saw firsthand how deeply cancer diagnosis and treatment can impact fertility, reproductive health, and life planning.
Now, the Dey Lab is taking the next step.
We are surveying biological female cancer patients diagnosed between ages 18–49 to better understand current practice patterns surrounding fertility counseling, preservation options, and reproductive health after a cancer diagnosis.

Your voice matters.
Your experience matters.
And your story can help improve care for future patients.
If you are eligible — or know someone who may be — please consider participating and sharing this flyer.

Use the link in the comment or scan the QR code above to access the survey.
Together, we can build a future where cancer care fully supports survivorship, fertility, and reproductive choice. 💜